Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DYAI NASDAQ:ERYP NASDAQ:GMDA NASDAQ:SLDB NASDAQ:XFOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYAIDyadic International$0.99-1.1%$1.00$0.91▼$2.20$30.09M0.8854,721 shs19,104 shsERYPERYTECH Pharma$3.10$4.66$0.30▼$1.47$105.77M2.6993,510 shsN/AGMDAGamida Cell$0.17$0.03▼$2.51$5.04M0.939.20 million shs23.04 million shsSLDBSolid Biosciences$5.26-3.0%$4.00$2.41▼$10.37$420.13M2.341.21 million shs610,739 shsXFORX4 Pharmaceuticals$1.43-8.9%$2.85$1.41▼$26.96$9.09M0.54142,894 shs645,315 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYAIDyadic International-1.07%+6.25%-1.08%-20.10%-27.80%ERYPERYTECH Pharma0.00%0.00%0.00%0.00%0.00%GMDAGamida Cell0.00%0.00%0.00%0.00%0.00%SLDBSolid Biosciences-2.95%+5.71%+14.10%+94.81%-24.96%XFORX4 Pharmaceuticals-8.92%-27.23%-55.31%-77.30%-92.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDYAIDyadic International2.8684 of 5 stars3.55.00.00.02.21.70.0ERYPERYTECH PharmaN/AN/AN/AN/AN/AN/AN/AN/AGMDAGamida CellN/AN/AN/AN/AN/AN/AN/AN/ASLDBSolid Biosciences3.1375 of 5 stars4.61.00.00.02.61.70.6XFORX4 Pharmaceuticals4.9408 of 5 stars3.54.00.04.62.93.32.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDYAIDyadic International 3.00Buy$6.00506.55% UpsideERYPERYTECH Pharma 0.00N/AN/AN/AGMDAGamida Cell 0.00N/AN/AN/ASLDBSolid Biosciences 3.17Buy$15.10187.07% UpsideXFORX4 Pharmaceuticals 3.00Buy$72.334,958.28% UpsideCurrent Analyst Ratings BreakdownLatest XFOR, DYAI, SLDB, ERYP, and GMDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/17/2025SLDBSolid BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/6/2025SLDBSolid BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$15.005/22/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$16.005/19/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/16/2025SLDBSolid BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$20.00 ➝ $17.005/16/2025SLDBSolid BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$15.00 ➝ $10.005/16/2025SLDBSolid BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$18.00 ➝ $17.005/13/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/2/2025XFORX4 PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.50 ➝ $7.00(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDYAIDyadic International$3.49M8.53N/AN/A$0.08 per share12.37ERYPERYTECH Pharma$32.66M3.24N/AN/A$0.80 per share3.88GMDAGamida Cell$1.78M0.00N/AN/A($0.02) per share0.00SLDBSolid Biosciences$8.09M50.40N/AN/A$3.43 per share1.53XFORX4 Pharmaceuticals$2.56M3.23N/AN/A$3.90 per share0.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDYAIDyadic International-$5.81M-$0.20N/AN/AN/A-163.94%-233.69%-59.37%8/12/2025 (Estimated)ERYPERYTECH Pharma-$240KN/A0.00∞N/AN/AN/AN/AN/AGMDAGamida Cell-$63M-$0.63N/AN/AN/AN/AN/A-57.59%N/ASLDBSolid Biosciences-$124.70M-$2.99N/AN/AN/AN/A-68.15%-55.33%8/12/2025 (Estimated)XFORX4 Pharmaceuticals-$37.45M$2.140.67N/AN/A46.54%-181.56%-54.36%8/6/2025 (Estimated)Latest XFOR, DYAI, SLDB, ERYP, and GMDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SLDBSolid Biosciences-$0.53-$0.59-$0.06-$0.59N/AN/A5/14/2025Q1 2025DYAIDyadic InternationalN/A-$0.07N/A-$0.07N/A$0.39 million5/1/2025Q1 2025XFORX4 Pharmaceuticals-$4.13$0.04+$4.17$0.04$7.03 million$28.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDYAIDyadic InternationalN/AN/AN/AN/AN/AERYPERYTECH PharmaN/AN/AN/AN/AN/AGMDAGamida CellN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/AXFORX4 PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDYAIDyadic International5.403.983.98ERYPERYTECH Pharma0.323.653.65GMDAGamida Cell213.142.162.09SLDBSolid BiosciencesN/A10.8910.89XFORX4 Pharmaceuticals3.303.703.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDYAIDyadic International27.95%ERYPERYTECH Pharma1.09%GMDAGamida Cell50.34%SLDBSolid Biosciences81.46%XFORX4 Pharmaceuticals72.03%Insider OwnershipCompanyInsider OwnershipDYAIDyadic International29.50%ERYPERYTECH Pharma1.94%GMDAGamida Cell3.40%SLDBSolid Biosciences1.90%XFORX4 Pharmaceuticals2.37%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDYAIDyadic International730.09 million21.21 millionOptionableERYPERYTECH Pharma4934.12 million33.46 millionNot OptionableGMDAGamida Cell143154.05 million143.70 millionOptionableSLDBSolid Biosciences10077.51 million76.04 millionOptionableXFORX4 Pharmaceuticals805.79 million5.65 millionOptionableXFOR, DYAI, SLDB, ERYP, and GMDA HeadlinesRecent News About These CompaniesX4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 0.3% - Should You Sell?July 10 at 2:23 AM | americanbankingnews.comX4 Pharmaceuticals, Inc. (XFOR) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comX4 Pharmaceuticals Inc News (XFOR) - Investing.comJuly 2, 2025 | investing.comXFOR X4 Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comX4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)June 16, 2025 | globenewswire.comX4 Pharmaceuticals Gets Fast Track Regulatory Designation for Neutropenia DrugJune 10, 2025 | marketwatch.comX4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropeniaJune 10, 2025 | msn.comX4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDAJune 10, 2025 | globenewswire.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | globenewswire.comX4 Pharmaceuticals Reports Positive Phase 2 Trial Results for Mavorixafor in Chronic Neutropenia, Accepted for Presentation at EHA CongressMay 16, 2025 | nasdaq.comX4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA CongressMay 14, 2025 | globenewswire.comX4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ...May 2, 2025 | finance.yahoo.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2025 Earnings Call TranscriptMay 2, 2025 | insidermonkey.comX4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call TranscriptMay 1, 2025 | seekingalpha.comX4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 1, 2025 | finance.yahoo.comX4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 1, 2025 | globenewswire.comX4 Pharmaceuticals Q1 2025 Earnings PreviewApril 30, 2025 | msn.comX4 Pharmaceuticals Analyst RatingsApril 30, 2025 | benzinga.comEarnings Preview For X4 PharmaceuticalsApril 30, 2025 | benzinga.comWhy X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025April 30, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseSarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesBy Leo Miller | June 18, 2025View Sarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesXFOR, DYAI, SLDB, ERYP, and GMDA Company DescriptionsDyadic International NASDAQ:DYAI$0.99 -0.01 (-1.07%) Closing price 07/11/2025 03:49 PM EasternExtended Trading$0.99 +0.00 (+0.28%) As of 07/11/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.ERYTECH Pharma NASDAQ:ERYPERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.Gamida Cell NASDAQ:GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.Solid Biosciences NASDAQ:SLDB$5.26 -0.16 (-2.95%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$5.27 +0.01 (+0.21%) As of 07/11/2025 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.X4 Pharmaceuticals NASDAQ:XFOR$1.43 -0.14 (-8.92%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.44 +0.02 (+1.05%) As of 07/11/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
